Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 301–400 of 879
Insulin Resistance: Pathophysiology and Rationale for Treatment
Muntoni, S., & Muntoni, S. (2011) · Annals of Nutrition and Metabolism · doi:10.1159/000323395 · Cited by 42
Glycemic Variability in Type 2 Diabetes Mellitus: Oxidative Stress and Macrovascular Complications
Johnson, E. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_13 · Cited by 38
Bauduceau, B., Floch, J. P. L., Halimi, S., Verny, C., Doucet, J., & Intergroup, T. S. (2017) · Diabetes Care · doi:10.2337/dc17-1437 · Cited by 38
Is Awareness of Chronic Kidney Disease Associated with Evidence-Based Guideline-Concordant Outcomes?
Tuot, D. S., Plantinga, L., Hsu, C., & Powe, N. R. (2012) · American Journal of Nephrology · doi:10.1159/000335935 · Cited by 33
Laiteerapong, N., Fairchild, P. C., Chou, C.-H., Chin, M. H., & Huang, E. S. (2014) · Medical Care · doi:10.1097/mlr.0000000000000255 · Cited by 34
Recent advances in the prevention of secondary ischemic stroke: A narrative review
Qiao, Y., Fayyaz, A. I., Ding, Y., Ji, X., & Zhao, W. (2024) · Brain Circulation · doi:10.4103/bc.bc_159_24 · Cited by 39
The assessment and management of quality of life of older adults with diabetes mellitus
Kassem, L. S., & Aron, D. C. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1737520 · Cited by 40
Chan, J. C. N., Ozaki, R., Luk, A. O. Y., Kong, A. P. S., Ronald, C. W., Chow, F. C. C., Wong, P., Wong, R. Y. M., Chung, H. H. Y., Chiu, C., et al. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70733-8 · Cited by 34
2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea
Ko, S., Kim, D. J., Oh, S., Lee, H.-J., Shim, K. H., Woo, M.-H., Kim, J., Kim, N. H., Kim, J.-T., Kim, C. H., et al. (2011) · Journal of Korean Diabetes · doi:10.4093/jkd.2011.12.4.183 · Cited by 31
Wu, C., Lai, M., & Gau, S. S. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.143925 · Cited by 31
On behalf of the UTOPIA study investigators, Katakami, N., Mita, T., Yoshii, H., Shiraiwa, T., Yasuda, T., Okada, Y., Umayahara, Y., Kaneto, H., Osonoi, T., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0292-1 · Cited by 32
Liu, L., Wang, F., Gracely, E. J., Moore, K., Melly, S. J., Zhang, F., Sato, P. Y., & Eisen, H. J. (2020) · Health Equity · doi:10.1089/heq.2020.0076 · Cited by 38
Saxagliptin: A Review in Type 2 Diabetes
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0473-z · Cited by 35
Tien, K., Yang, C.-Y., Weng, S., Liu, S.-Y., Hsieh, M., & Chou, C. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.03.010 · Cited by 32
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Khunti, K., & Davies, M. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01186.x · Cited by 34
The evolving natural history of neurophysiologic function in patients with well‐controlled diabetes
Gibbons, C. H., Freeman, R. L., Tecilazich, F., Dinh, T., Lyons, T. E., Gnardellis, C., & Veves, A. (2013) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12021 · Cited by 30
Tunis, S. L., Minshall, M. E., Conner, C., McCormick, J. I., Kapor, J., Yale, J., & Groleau, D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902869169 · Cited by 32
Urothelial Dysfunction and Chronic Inflammation in Diabetic Patients with Overactive Bladder
Chung‐Cheng, W. A. N. G., & Kuo, H. (2016) · LUTS Lower Urinary Tract Symptoms · doi:10.1111/luts.12126 · Cited by 31
Aguilar, R. B. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.008 · Cited by 34
Hypoglycemia as a Driver of Cardiovascular Risk in Diabetes
Moheet, A. A., & Seaquist, E. R. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0351-7 · Cited by 33
Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor?
Rana, O. A., Byrne, C. D., & Greaves, K. (2013) · Heart · doi:10.1136/heartjnl-2013-303871 · Cited by 34
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
Cutruzzolà, A., Irace, C., Parise, M., Fiorentino, R., Tripodi, P. F. P., Ungaro, S., Babinsky, V. N., & Gnasso, A. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.06.009 · Cited by 32
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.
Brunetti, L., & Kalabalik, J. (2012) · PubMed · Cited by 63
McCullough, P. A., & Verrill, T. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2119 · Cited by 38
Tunis, S. L., & Minshall, M. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903400071 · Cited by 33
Insights into the pathogenesis and treatment of painful diabetic neuropathy
Greig, M., Tesfaye, S. H., Selvarajah, D., & Wilkinson, I. D. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00037-0 · Cited by 34
Pettit, S., Cresta, E., Winkley, K., Purssell, E., & Armes, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176941 · Cited by 35
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2054 · Cited by 37
Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach
Ceriello, A., Gallo, M., Candido, R., Esposito, K., Gnetile, S., Medea, G., & Micheli, A. D. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s50288 · Cited by 31
Pharmacist-Physician Collaboration for Diabetes Care: Cardiovascular Outcomes
Howard-Thompson, A., Farland, M. Z., Byrd, D. C., Airee, A., Thomas, J., Campbell, J., Cassidy, R., Morgan, T., & Suda, K. J. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504738 · Cited by 34
The Use of Echocardiography and Advanced Cardiac Ultrasonography During Pregnancy
O’Kelly, A. C., Sharma, G. V., Vaught, A. “. J., & Zakaria, S. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0785-5 · Cited by 33
Yin, Z., Fan, L., Wei, L., Gao, H., Zhang, R., Tao, L., Cao, F., & Wang, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042900 · Cited by 29
Bittencourt, C., Piveta, V. M., Oliveira, C. S. V., Crispim, F., Meira, D. M., Saddi-Rosa, P., Giuffrida, F. M. A., & Reis, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-46 · Cited by 32
The bigger, the better? When multicenter clinical trials and meta-analyses do not work
Seifirad, S., & Alquran, L. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1860922 · Cited by 30
Li, C., Kuo, C., Chang, Y., Lu, C., Martini, S., & Hou, W. (2021) · Journal of Epidemiology · doi:10.2188/jea.je20200518 · Cited by 29
Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia
Shogbon, A. O., & Levy, S. B. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090211 · Cited by 29
Diabetic Cardiovascular Disease: Getting to the Heart of the Matter
Peterson, L. R., McKenzie, C. R., & Schaffer, J. E. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9374-7 · Cited by 33
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 50
Self-citationThind, H. K., Fava, J. L., Guthrie, K. M., Stroud, L. R., Gopalakrishnan, G., Sillice, M. A., Gidron, N., & Bock, B. C. (2018) · International Journal of Yoga Therapy · doi:10.17761/2018-00026 · Cited by 35
Baruah, M., Kalra, S., Unnikrishnan, A., Raza, S., Somasundaram, N. P., John, M., Katulanda, P., Shrestha, D., Bantwal, G., Sahay, R. K., et al. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81935 · Cited by 32
Indikation und Prinzipien der metabolischen Chirurgie
Weiner, R. A. (2010) · Der Chirurg · doi:10.1007/s00104-009-1859-9 · Cited by 36
Neugebauer, R. S., Schmittdiel, J. A., & van der Laan, M. J. (2016) · The International Journal of Biostatistics · doi:10.1515/ijb-2015-0028 · Cited by 33
Chen, T., Xiao, S., Chen, Z., Yang, Y., Yang, B., & Liu, N. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111079 · Cited by 39
Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
Ovalle, F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.006 · Cited by 28
Novedades en hipertensión arterial y diabetes mellitus
Cordero, A., Fácila, L., Galve, E., & Mazón, P. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70144-5 · Cited by 30
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia
Madonna, R., & Caterina, R. D. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.009 · Cited by 34
Sullivan, S. D., Alfonso‐Cristancho, R., Conner, C., Hammer, M., & Blonde, L. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-12 · Cited by 28
Management of the Diabetic Patient with Advanced Chronic Kidney Disease
Alicic, R. Z., & Tuttle, K. R. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00700.x · Cited by 28
Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?
Mathur, S., Zammitt, N. N., & Frier, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0247-7 · Cited by 30
Aterogénesis y diabetes: resistencia a la insulina e hiperinsulinemia
Madonna, R., & Caterina, R. D. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.11.010 · Cited by 34
On behalf of the PROTECT Study Investigators, Tanaka, A., Murohara, T., Taguchi, I., Eguchi, K., Suzuki, M., Kitakaze, M., Sato, Y., Ishizu, T., Higashi, Y., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0449-7 · Cited by 27
Is Hba1c level of diabetic patients associated with penile prosthesis implantation infections?
Cangüven, Ö., Talib, R. A., Ansari, W. E., Khalafalla, K. M., & Ansari, A. A. (2018) · The Aging Male · doi:10.1080/13685538.2018.1448059 · Cited by 27
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 27
Kim, E. S., Mo, E. Y., Moon, S. D., & Han, J. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109251 · Cited by 26
Younk, L. M., Uhl, L., & Davis, S. N. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.579561 · Cited by 26
Wang, X., Wang, Z., Liu, D., Jiang, H., Cai, C., Li, G., & Yu, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.839640 · Cited by 31
Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus
Kim, J., & Kwon, H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0377 · Cited by 33
Fu, S. N., Chin, W. Y., Wong, C. K. H., Yeung, V. T. F., Yiu, M. P., Tsui, H., & Chan, K. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078933 · Cited by 29
Tunis, S. L., Willis, W. D., & FOOS, V. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903429765 · Cited by 27
Ceriello, A., Gallo, M., Armentano, V., Perriello, G., Gentile, S., & Micheli, O. B. O. T. A. A. D. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0233 · Cited by 31
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 31
A Blockchain Framework for Managing and Monitoring Data in Multi-Site Clinical TrialsPreprint
Choudhury, O., Fairoza, N., Sylla, I., & Das, A. K. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1902.03975 · Cited by 44
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition)
Dedov, I. I., Shestakova, M. V., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Кураева, Т. Л., Липатов, Д. В., Mayorov, A. Y., Peterkova, V. A., et al. (2015) · Diabetes Mellitus · doi:10.14341/dm7078 · Cited by 28
Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes
Ajjan, R., & Owen, K. R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0559-0 · Cited by 25
Interpreting Adverse Signals in Diabetes Drug Development Programs
Bailey, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-0182 · Cited by 30
Ma, J., Liu, L. Y., Wu, P., Liao, Y., Tao, T., & Liu, W. (2014) · Journal of Diabetes Research · doi:10.1155/2014/294017 · Cited by 27
Hemmingsen, B., Lund, S. S., Wetterslev, J., & Vaag, A. A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0167 · Cited by 27
Bando, Y., Tohyama, H., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K., & Toya, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.06.001 · Cited by 25
Gavin, T. P., Ernst, J. M., Kwak, H., Caudill, S. E., Reed, M. A., Garner, R. T., Nie, Y., Weiss, J. A., Pories, W. J., Dar, M. S., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01727 · Cited by 25
Suh, S., Seo, G. H., Jung, C. H., Kim, M.-K., Jin, S., Hwang, Y., Lee, B., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.3.247 · Cited by 25
The Role of Nursing Home Admission and Dementia Status on Care for Diabetes Mellitus
Quinn, C. C., Gruber‐Baldini, A. L., Port, C. L., May, C., Stuart, B., Hebel, J. R., Zimmerman, S. I., Burton, L. C., Zuckerman, I. H., Fahlman, C., et al. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02382.x · Cited by 25
Laiteerapong, N., John, P. M., Nathan, A. G., & Huang, E. S. (2012) · Diabetes Care · doi:10.2337/dc11-2344 · Cited by 28
Shi, L., Ye, X., Lü, M., Wu, E. Q., Sharma, H., Thomason, D., & Fonseca, V. A. (2013) · Diabetes Care · doi:10.2337/dc13-0149 · Cited by 27
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
Gaebler, J., Soto-Campos, G., Alperin, P., Cohen, M., Blickensderfer, A., Wintle, M., Maggs, D., Hoogwerf, B., Han, J., Pencek, R., et al. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28744 · Cited by 25
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 29
Type 2 Diabetes Mellitus: Managing Hemoglobin A1c and Beyond
Fowler, G. C., & Vasudevan, D. A. (2010) · Southern Medical Journal · doi:10.1097/smj.0b013e3181eb34b2 · Cited by 34
Exercise and Postprandial Glycemic Control in Type 2 Diabetes
Kearney, M. L., & Thyfault, J. P. (2016) · Current Diabetes Reviews · doi:10.2174/1573399811666150615112441 · Cited by 29
Diabetic nephropathy--the family physician's role.
Roett, M. A., Liegl, S., & Jabbarpour, Y. (2012) · PubMed · Cited by 33
Diabetes, Insulin and Alzheimer's Disease
Craft, S., & Christen, Y. (2010) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-04300-0 · Cited by 27
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Escalada, J., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.04.005 · Cited by 29
Cobble, M. E. (2012) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-4-8 · Cited by 26
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Ikeda, M., & Shimazawa, R. (2019) · Journal of General and Family Medicine · doi:10.1002/jgf2.244 · Cited by 28
New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals
Wysham, C. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2142 · Cited by 23
Prevention and management of chronic kidney disease in type 2 diabetes
Chadban, S. J., Howell, M., Twigg, S. M., Thomas, M. C., Jerums, G., Cass, A., Campbell, D. A., Nicholls, K., Tong, A., Mangos, G., et al. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01240.x · Cited by 29
Rajendran, R., Hodgkinson, D. W., & Rayman, G. A. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132926 · Cited by 21
Kümler, T., Gislason, G., Køber, L., & Torp-Pedersen, C. T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-22 · Cited by 22
The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes
Paty, B. W. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.009 · Cited by 26
Magnan, E. M., Bolt, D. M., Greenlee, R. T., Fink, J. T., & Smith, M. A. (2016) · Health Services Research · doi:10.1111/1475-6773.12607 · Cited by 23
Ramirez, F. D., Chen, Y., Santo, P. D., Simard, T., Motazedian, P., & Hibbert, B. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005491 · Cited by 24
Zu, Y., Wan, L.-J., Cui, S., Gong, Y., & Li, C. (2015) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2015.03.003 · Cited by 27
Kusunoki, Y., Katsuno, T., Nakae, R., Watanabe, K., Akagami, T., Ochi, F., Tokuda, M., Murai, K., Miuchi, M., Miyagawa, J., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.040 · Cited by 24
Lund, S. S., & Vaag, A. A. (2009) · Diabetes Care · doi:10.2337/dc09-9030 · Cited by 20
Milligan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.010 · Cited by 23
Zarowitz, B. J. M., & Conner, C. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.pt2.55s · Cited by 20
Should A1C Targets Be Individualized for All People With Diabetes?
Teoh, H., Home, P., & Leiter, L. A. (2011) · Diabetes Care · doi:10.2337/dc11-s217 · Cited by 23
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.